Propanc PRP Pancreatic Cancer Data
Analysis based on 11 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
The announcement highlights Propanc's differentiated mechanism and potential to address resistance in pancreatic cancer, which could positively influence investor sentiment for the company. It also underscores the competitive landscape in PDAC treatment, potentially affecting Revolution Medicines' market positioning.
Propanc Biopharma announced compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patient-derived xenograft models, PRP achieved greater than 90% tumor growth inhibition, reduced metastatic burden, remodeled the tumor microenvironment, enhanced sensitivity of chemo-resistant cells to gemcitabine/nab-paclitaxel, and extended median overall survival by more than 2.5-fold. The company compared its approach to Revolution Medicines' daraxonrasib, which recently delivered Phase 3 results in metastatic PDAC. PRP holds FDA Orphan Drug Designation and is not limited to specific RAS mutations. Propanc is accelerating its Phase 1b First-in-Human study in advanced solid tumors, with a clinical trial application expected in the coming months.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard